Yamo Pharmaceuticals is developing L1-79, an investigational compound for the treatment of autism.
L1-79 is a new investigational drug that appears to improve the core symptoms associated with autism. L1-79 has been administered to over 40 people and has been well-tolerated to date.
But we need to learn more and we need your help!
Yamo Pharmaceuticals is actively seeking to identify participants for future clinical studies of L1-79. A 250-patient Phase 2b study is planned to commence under FDA oversight in early 2019. Clinical studies are needed to prove that drugs are safe and effective.
Please take a moment to fill out the form on our Contact Us page. If the person qualifies for a future study based on the answers to the eligibility questions, our study director will contact you shortly with more details.